SLDB
Solid Biosciences Inc.
$9.62
-0.01 (-0.10%)
At close · Jul 15
Market Cap
$887.52M
Shares
98,449,606
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.62
Open$9.59
Day$9.34–9.79
52W$3.79–11.45
Avg vol 30d2.3M
Short int18.3M · 18.6% float · 4.6d
Short vol47%
Last earningsFeb 18, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+20%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
76%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+31%
trailing
6-month return
+56%
trailing
YTD return
+71%
this year
Relative strength
+46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
4 of 144 funds reported for Jun 30 · net +110.4K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.56% of float · ▲ +57.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
144 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
−41%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-157.4M
Balance sheet
$59.9M
net cash
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
76%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
4 of 144 funds reported for Jun 30 · net +110.4K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
18.56% of float · ▲ +57.3% MoM · 4.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
144 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $10 · 76%
52-wk high $11
vs 200-day avg +44%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLDB
this stock
Solid Biosciences Inc.
|
$887.52M | +70.6% | -40.6% | — | 18.6% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLDB | -12.6% | +30.7% | +56.2% | -3.7% | +70.6% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -13.8% | +30.9% | +46.0% | -4.8% | +59.9% |